Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.

Alcohol Withdrawal Syndrome Clinical Trial

— RESC  

Official title:

Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02146716
• Other study ID #: 2013-840
• Status: Completed
• Phase: N/A
• First received: May 19, 2014
• Last updated: August 22, 2017
• Start date: May 2014
• Est. completion date: February 2017

Study information

• Verified date: August 2017
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of RESC study is to assess the efficacy of Energetic Resonance by Cutaneous Stimulation on alcohol withdrawal symptoms measured by CUSHMAN score and in a second time to measure the benzodiazepine amount prescribed during the withdrawal time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: February 2017
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Men and women between 18 and 80 years,

• Patient with alcohol addiction,

• Patient needing alcohol withdrawal in a hospital.

• Patient with social Security,

• Patient with inform consent signed.

Exclusion Criteria:

• Pregnant women

• Minor.

• Major with guardianship.

• People without sufficient information because of troubles of cognitive functions, or without sufficient knowledge of French language.

Related Conditions & MeSH terms

• Alcohol Withdrawal Syndrome
• Substance Withdrawal Syndrome

Intervention

Other:
• Energetic Resonance by Cutaneous Stimulation
Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.

Locations

Country	Name	City	State
France	Hôpital croix rousse	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cushman Score measure after Energetic Resonance by Cutaneous Stimulation	CUSHMAN score is represented by a scale with 7 variables collecting physiological modifications or behavioural manifestations related to adrenergic answer, neurovegetative signs, confusion, nervousness, perceptive or hallucinatory phenomena.	daily during one week
Secondary	Anxiety depression scale		pre-screening, day 3 and day 7
Secondary	prescribed benzodiazepine amount		day 0 to day 7
Secondary	Analogic Visual Scale		before and after each Energetic Resonance by Cutaneous Stimulationsession at day 2, day 4 and day 6.
Secondary	Quality of life scale		day 0